These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 18760876)

  • 1. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity.
    Lin CY; Chuang TF; Liao KW; Huang YJ; Pai CC; Chu RM
    Cancer Lett; 2008 Dec; 272(2):285-95. PubMed ID: 18760876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of immunotherapy of IL-6 and IL-15 plasmids on transmissible venereal tumor in beagles.
    Chou PC; Chuang TF; Jan TR; Gion HC; Huang YC; Lei HJ; Chen WY; Chu RM
    Vet Immunol Immunopathol; 2009 Jul; 130(1-2):25-34. PubMed ID: 19200609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The lack of NK cytotoxicity associated with fresh HUCB may be due to the presence of soluble HLA in the serum.
    Webb BJ; Bochan MR; Montel A; Padilla LM; Brahmi Z
    Cell Immunol; 1994 Dec; 159(2):246-61. PubMed ID: 7994757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.
    Raja Gabaglia C; Diaz de Durana Y; Graham FL; Gauldie J; Sercarz EE; Braciak TA
    Cancer Res; 2007 Mar; 67(5):2290-7. PubMed ID: 17332360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depletion of IL-10- and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells.
    Seo N; Tokura Y; Takigawa M; Egawa K
    J Immunol; 1999 Jul; 163(1):242-9. PubMed ID: 10384122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
    J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
    Kasid A; Bell GI; Director EP
    J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
    Arteaga CL; Hurd SD; Winnier AR; Johnson MD; Fendly BM; Forbes JT
    J Clin Invest; 1993 Dec; 92(6):2569-76. PubMed ID: 7504687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K; Varalakshmi C; Khar A
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer.
    Suzuki K; Nakazato H; Matsui H; Hasumi M; Shibata Y; Ito K; Fukabori Y; Kurokawa K; Yamanaka H
    J Leukoc Biol; 2001 Apr; 69(4):531-7. PubMed ID: 11310838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-10 reduces natural killer (NK) sensitivity of tumor cells by downregulating NK target structure expression.
    Tsuruma T; Yagihashi A; Hirata K; Torigoe T; Araya J; Watanabe N; Sato N
    Cell Immunol; 1999 Dec; 198(2):103-10. PubMed ID: 10648124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations.
    Evans R; Fuller JA; Christianson G; Krupke DM; Troutt AB
    Cell Immunol; 1997 Jul; 179(1):66-73. PubMed ID: 9259773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intradermal delivery of IL-12 naked DNA induces systemic NK cell activation and Th1 response in vivo that is independent of endogenous IL-12 production.
    Watanabe M; Fenton RG; Wigginton JM; McCormick KL; Volker KM; Fogler WE; Roessler PG; Wiltrout RH
    J Immunol; 1999 Aug; 163(4):1943-50. PubMed ID: 10438930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-7 selectively enhances natural kill cytotoxicity mediated by the CD56bright natural killer subpopulation.
    Dadmarz R; Bockstoce DC; Golub SH
    Lymphokine Cytokine Res; 1994 Dec; 13(6):349-57. PubMed ID: 7535569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects.
    Ugai S; Shimozato O; Yu L; Wang YQ; Kawamura K; Yamamoto H; Yamaguchi T; Saisho H; Sakiyama S; Tagawa M
    Cancer Gene Ther; 2003 Oct; 10(10):771-8. PubMed ID: 14502230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
    Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
    J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model.
    Dorigo O; Shawler DL; Royston I; Sobol RE; Berek JS; Fakhrai H
    Gynecol Oncol; 1998 Nov; 71(2):204-10. PubMed ID: 9826461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-10 reduces natural killer sensitivity and downregulates MHC class I expression on H-ras-transformed cells.
    Tsuruma T; Yagihashi A; Torigoe T; Sato N; Kikuchi K; Watanabe N; Hirata K
    Cell Immunol; 1998 Mar; 184(2):121-8. PubMed ID: 9630838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-2/IL-18 prevent the down-modulation of NKG2D by TGF-beta in NK cells via the c-Jun N-terminal kinase (JNK) pathway.
    Song H; Hur DY; Kim KE; Park H; Kim T; Kim CW; Bang S; Cho DH
    Cell Immunol; 2006 Jul; 242(1):39-45. PubMed ID: 17070508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.